A young man with numbness in arms and legs from the National Multiple Sclerosis Society Case Conference Proceedings

TY - JOUR

T1 - A young man with numbness in arms and legs from the National Multiple Sclerosis Society Case Conference Proceedings

AU - Romeo, Andrew R.

AU - Lisak, Robert P.

AU - Meltzer, Ethan

AU - Fox, Edward J.

AU - Melamed, Esther

AU - Lucas, Ashlea

AU - Freeman, Leorah

AU - Frohman, Teresa C.

AU - Costello, Kathleen

AU - Zamvil, Scott S.

AU - Frohman, Elliot M.

AU - Gelfand, Jeffrey M.

N1 - Funding Information: The Article Processing Charge was funded by the National Multiple Sclerosis Society. Funding Information: Probable neurosarcoidosis, manifesting as a partial longitudinally extensive transverse cervical myelitis, supported by biopsy-confirmed pulmonary sarcoidosis. Funding Information: The authors wish to express their gratitude to their medical illustrator, Mr. Jason Ooi, for his evidence-based rendition of the putative mechanisms underlying noncaseating granulomatous inflammation in neurosarcoidosis. The authors also wish to acknowledge the UCSF MS EPIC Study Team. The National Multiple Sclerosis Society Case Conference Proceedings is a peer review publishing initiative from the monthly; Diagnostic and Treatment Challenges in MS and Neuroimmunology Webinars; sponsored by the National Multiple Sclerosis Society Fellowship Training Program; and Directed by Elliot M Frohman, MD, PhD. Funding Information: Diagnostic and Treatment Challenges in MS and Neuro-immunology Webinars is sponsored by the National Multiple Sclerosis Fellowship Training Program. Funding Information: A.R. Romeo received research support from National Multiple Sclerosis Society. R.P. Lisak served on the scientific advisory board from Syntimmune, Alexion, National Multiple Sclerosis Society, Myasthenia Gravis Foundation of America, Guillain-Barre Syndrome/CIDP Foundation; received travel funding and/or speaker honoraria from Teva; is section editor for Neuroimmunology, Clinical Neuropharmacology; is on the editorial board for Immunology Research; receives publishing royalties from Blackwell and Oxford; consulted for GLG Consulting, Insight Consulting, Alpha Sites Consulting, Slingshot Consulting, Informa Pharma Consulting; served on the speaker’s bureau for Teva; is immediate past president and member of Consortium of Multiple Sclerosis Centers; is on the Executive Committee of the Board of Directors; is member of the Board of Governors of the Foundation of the Consortium of Multiple Sclerosis Centers Society; is on the Board of Governors for National Multiple Sclerosis Society; received research support from Teva, Alexion, Genentec, Novartis, Medimmune, Chigai, Ra Pharmaceuticals paid to Wayne State University. E. Meltzer reports no disclosures. E.J. Fox served on the scientific advisory board for Acorda, Bayer, Biogen, EMD Serono, Genentech Roche, Novartis, Sanofi Genzyme, Teva; received travel funding and speaker honoraria from Acorda, Biogen, EMD Serono, Genentech Roche, Novartis, Sanofi Genzyme, Teva; consulted for Bayer, Biogen, EMD Serono, Genentech Roche, Novartis, Sanofi Genzyme, Teva; served on the speaker’s bureau for Acorda, Biogen, EMD Serono, Genentech Roche, Novartis, Sanofi Genzyme, Teva; received research support from Biogen, Celgene, Chugai, EMD Serono, Genentech Roche, Mallinckrodt, MedDay, Novartis, Sanofi Genzyme, Teva, TG Therapeutics, National Multiple Sclerosis Society; provided expert testimony for Teva. E. Melamed served on the scientific advisory board for EMD, received research support from William & Ella Owens Medical Research Foundation. A. Lucas and L. Freeman report no disclosures. T.C. Frohman received travel funding and/or speaker honoraria from Novartis, Acorda, Genzyme, Biogen; is on the editorial board for NMSS Publication; receives publishing royalties for UpToDate; consulted for Acorda, Novartis, Genzyme; received research support from NIH and NMSS. K. Costello received travel funding from Advanced Studies in Medicine, Johns Hopkins Medicine. S.S. Zamvil served on data safety monitoring boards for Opexa, BioMS, Teva, and Eli Lilly; is a member of the clinical advisory board for Myelin Repair Foundation; is deputy editor for Neurology: Neuroimmunology & Neuro-inflammation; holds a patent for Aquaporin-4 peptides; consulted for Biogen, Teva, EMD-Serono, Genzyme, Novartis, Roche; serves on the speaker’s bureau for Advanced Health Media, Biogen; received research support from Biogen, Teva, NIH, NMSS, Alexander M. and June L. Maisin Foundation. E.M. Frohman received speaker honoraria from Genzyme, Novarits, Acorda; served on the editorial board for Journal of Neurology, Journal of Neurology, Neurosurgery, and Psychiatry; receives publishing royalties from UpToDate, Cambridge University Press; served on the speaker’s bureau from Gen-zyme, Novartis, Acorda; received research support from National Multiple Sclerosis Society. J.M. Gelfand is on the editorial board for Neurology: Neuroimmunology & Neuro-inflammation; consulted for Biogen; received research support to University of California, San Francisco from Genentech, MedDay, Quest Diagnostics; received research support from National Multiple Sclerosis Society, received compensation for medical-legal consulting; his spouse is an associate editor for JAMA Neurology, received honoraria from UpToDate, consulted for Zosano, Eli Lilly, Biohaven, and eNeura. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.

PY - 2018/11/1

Y1 - 2018/11/1

UR - http://www.scopus.com/inward/record.url?scp=85060930581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060930581&partnerID=8YFLogxK

U2 - 10.1212/NXI.0000000000000509

DO - 10.1212/NXI.0000000000000509

M3 - Article

C2 - 30465017

AN - SCOPUS:85060930581

VL - 5

JO - Neurology: Neuroimmunology and NeuroInflammation

JF - Neurology: Neuroimmunology and NeuroInflammation

SN - 2332-7812

IS - 6

M1 - e509

ER -